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Abstract
There is increasing evidence that temporal factors are
important in allowing cells to gain additional information
from external factors, such as hormones and cytokines. We
sought to discover how cell responses to glucocorticoids
develop over time, and how the response kinetics vary
according to ligand structure and concentration, and hence
have developed a continuous gene transcription measurement
system, based on an interleukin-6 (IL-6) luciferase reporter
gene. We measured the time to maximal response, maximal
response and integrated response, and have compared these
results with a conventional, end point glucocorticoid bioassay.
We studied natural glucocorticoids (corticosterone and
cortisol), synthetic glucocorticoids (dexamethasone) and
glucocorticoid precursors with weak, or absent bioactivity.
We found a close correlation between half maximal effective
concentration (EC50) for maximal response, and for
integrated response, but with consistently higher EC50 for
the latter. Therewas no relationbetween the concentration of
ligand and the time to maximal response. A comparison
between conventional end point assays and real-time
measurement showed similar effects for dexamethasone and
hydrocortisone, with a less effective inhibition of IL-6 seen
with corticosterone. We proﬁled the activity of precursor
steroids, and found pregnenolone, progesterone, 21-hydroxy-
progesterone and 17-hydroxyprogesterone all to be ineffective
in the real-time assay, but in contrast, progesterone and
21-hydroxyprogesterone showed an IL-6 inhibitory activity
in the end point assay. Taken together, our data show how
ligand concentration can alter the amplitude of glucocorti-
coid response, and also that a comparison between real-time
and end point assays reveals an unexpected diversity of the
function of glucocorticoid precursor steroids, with impli-
cations for human disorders associated with their
overproduction.
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Introduction
Glucocorticoid hormones exert a wide diversity of effects in
target tissues. Their activity has been typically explored using
a limited number of timed end points, both in vivo and in vitro,
and using such approaches a variety of synthetic analogues
have been developed for use in inﬂammatory conditions
(Hillier 2007). Some agents, such as dexamethasone, show
increased selectivity of action towards glucocorticoid
pathways as opposed to mineralocorticoid (Hillier 2007).
It has recently become clear that even minor changes to the
structure of a ligand can result in a distinct and unpredictable
pattern of activity (Wang et al. 2006). However, the effects of a
steroid can also be altered by varying its effective biological
half-life, as for dexamethasone (Samtani & Jusko 2005, 2007).
In vivo, the pharmacokinetics of steroids has been exploited to
introduce topical activity, by, for example, making steroid
structures susceptible to metabolism (e.g. budesonide;
Ryrfeldt et al. 1982, Brunner et al. 2006, Singh et al. 2007).
It is now possible to track target gene promoter activity
continuously, in real-time, without affecting cell viability.
This approach allows, for the ﬁrst time, temporal deconvolu-
tion of the effects of steroid, permitting robust measurement
of the time to onset of effect, maximal effect, integrated effect
and resolution phase. The luciferase reporter used in these
studies is unstable, and hence luciferase activity is dependent
on new gene transcription, a signiﬁcant advantage over more
stable reporter gene products, such as ﬂuorescent proteins
(Takasuka et al. 1998).
We have been able to establish a robust and sensitive assayof
glucocorticoid action using the repression of interleukin-6
(IL-6) promoter activity. IL-6 is a physiologically relevant
endogenous glucocorticoid receptor (GR) target gene and
is important in both the innate immune response and
the elaboration of the systemic response to inﬂammation
(DeBosscheretal.2005).Wewereabletoshowthatthreewell-
characterised glucocorticoid molecules all had the expected
ability to repress IL-6 transcription, and that three closely
related steroids did not. Furthermore, we were able to
distinguish between the concentration–maximal response,
the concentration-integrated response and the concentration-
independent time to maximal response for each steroid.
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using thisassay,ashydrocortisonewasfoundtobesigniﬁcantly
moreactivethaneithercorticosteroneordexamethasone.This
studyemphasisestheneedtoconsidereachspeciﬁceffectofthe
steroid independently.
Materials and Methods
Plasmid construction
The promoter region of human IL-6 was ampliﬁed from
human genomic DNA using the HiFi PCR kit (Roche)
following the manufacturer’s instructions. The primers were
designed to amplify from within the transcriptional start site
to the upstream promoter region yielding a 3000 bp fragment
(IL-6). The primers for 3000 bp IL-6 product are as follows:
FWD primer (IL-6F1): 50CAGATCCAGCAGCA-
CAGGAAG30
REV primer (IL-6R1): 50GATAGAGCTTCTCTTTC-
GTTCC30
Upon successful puriﬁcation, the DNA was adenylated
with the addition of an A overhang to the 30-end, allowing for
the subsequent ligation into the pCR2.1-TOPO subcloning
vector (Invitrogen). Inserts ligated in the correct orientation
in the TOPO TA vector were then cut out using restriction
enzymes EcoRVand KpnI. This would allow the insert to be
subsequently ligated in the destination vector, PGL4-basic
(Promega), in the correct orientation due to the presence of
the same restriction enzyme sites.
The PGL4-basic vector was digested using EcoRV and
KpnI. Both the PCR fragments and the newly cut vector
were then gel-extracted as before, and then each fragment
was ligated into the PGL4-basic vector using T4 ligase
(Roche). TOP 10 cells were transformed with the new
constructs, and grown as a single colony expansion. The
constructs were then isolated and puriﬁed using a MiniPrep
Kit (Qiagen). The constructs were externally sequenced
throughout the promoter fragment region (LARK Tech-
nologies, Thakeley, Essex, UK).
Cell culture and stable transfection
Rat-1 cells, a rat ﬁbroblast cell line known to express
glucocorticoid receptor, and to be glucocorticoid responsive,
were cultured at 37 8C (5% CO2) in high-glucose Dulbecco’s
modiﬁed Eagle’s medium; (DMEM; catalogue no. 11965-
092, Gibco) supplemented with 10% FBS (Gibco), and a
mixture of penicillin–streptomycin–glutamine (PSG from
Gibco no. 10378-016).
Stable transfection of Rat-1 cells was performed using
Fugene6 according to standard protocols. The transfected
cells were selected in 200 ug/ml hygromycin for 2 weeks after
which resistant clones were frozen at K80 8C until required
for further experiments. No phenotypic changes or growth
rate alterations were induced by the DNA construct.
End point luciferase assay
Approximately 1!10
6 cells were seeded in a 35 mm dish
4 days before the experiment and allowed to grow to
conﬂuence. The medium was changed and drug treatments
given. Treatments included dexamethasone (D1756; Sigma)
withaﬁnalconcentrationrangefrom0.1to1000 nM,5 ng/ml
tumour necrosis factor a (TNFa; Calbio, Nottingham, UK),
1000 nMprogesterone(Sigma–Aldrich),1000 nMpregneno-
lone acetate (Sigma–Aldrich), 1000 nM of 21-hydroxypro-
gesterone-21-acetate (Sigma–Aldrich), 1000 nM corticosterone
(Sigma–Aldrich), 1000 nM hydrocortisone and 1000 nM of
17-hydroxyprogesterone (Sigma–Aldrich).
After 24 h, luciferase assays were performed according to
the manufacturer’s instructions (Promega). Brieﬂy, the
medium was aspirated from the wells and 200 ml lysis buffer
was added. To 100 ml lysate was added 50 ml beetle luciferin
substrate (0.1 mM total luciferin) and the bioluminescence
was measured using the Mithras LB940 automated analyser
(Berthold Technologies East Grinstead, UK).
Real-time luciferase assay
Approximately 1!10
6 cells were seeded in a 35 mm dish
4 days before the experiment and allowed to grow to
conﬂuence. The medium was then replaced with the real-
time assay medium (serum-free DMEM without phenol red,
catalogue no. 13000-021, Gibco) supplemented with
bicarbonate (350 mg/l), 10% FBS and 10 mM HEPES (pH
7.2), antibiotics (25 units/ml penicillin, 25 mg/ml strepto-
mycin) and 0.1 mM luciferin (Promega). The 35 mm Petri
dishes are sealed with coverslips and silicon grease. The cells
were assayed using a custom-made apparatus based on that
developed by Takahashi et al. with luminescence measured
using Hamamatsu photon counting modules (Yoo et al. 2004).
After 48 h, the cells were removed from the photo-
multiplier tube and treated with the compounds directly in
the growth medium. The dishes were immediately resealed
and replaced into the photomultiplier tubes. Treatments
included dexamethasone (D1756; Sigma) with ﬁnal concen-
tration range from 0.1 to 1000 nM, 5 ng/ml TNFa (Calbio),
1000 nM progesterone, 1000 nM pregnenolone acetate,
1000 nM of 21-hydroxyprogesterone-21-acetate, 1000 nM
corticosterone, 1000 nM hydrocortisone and 1000 nM of
17-hydroxyprogesterone.
Photomultiplier tube data analysis
Datawere analysed to determine the effects of the various drug
treatments. A logarithmic trend line was ﬁtted using the data
obtainedfor48 hbeforethecommencementoftreatment.This
procedureremovedanybaselinenon-stationaritiesfromthedata
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ofthetreatmentperiod.Theeffectofcompoundtreatmentwas
calculatedusingdeviationfromthetrendline(Fig.1).Thetotal
level of induction/inhibition was calculated as the total sum of
deviation from the trend line.
Statistical analysis
Comparisons between groups were by ANOVA followed by
Bonferroni’s t-test.
Results
Kinetic deconvolution of glucocorticoid response
In analysing the effects of glucocorticoids ex vivo, a single end
point is analysed at a limited numberof time points. However,
the integrated glucocorticoid effect is determined by both the
amplitude of response and its duration. In order to track the
glucocorticoid response in real time, a continuous, non-
destructive cell-based assay was developed (Fig. 1). The cells
remain viable in this environment for up to 10 days (data not
shown), and the complete time course of glucocorticoid
response can be followed, allowing an accurate measurement
of the time to onset, duration, amplitude and integrated
response (area under the curve) to be determined (Fig. 1).
TNFa effects on IL-6-luc in real-time
TNFa is a major physiological regulator of the IL-6 gene
expression. To determine whether TNFa was also capable of
appropriately regulating the IL-6-luc reporter cell, the effects
of TNFa alone and those of dexamethasone were measured.
TNFa did induce IL-6-luc activity (as shown by a negative
inhibition on the graph), and this excursion was reversed by
co-incubation with dexamethasone (Fig. 2).
Dose–response of IL-6 response to glucocorticoid
The concentration–maximal inhibition relationship for IL-6
inhibition was determined using the continuous measure-
ment system (Fig. 3a), which allowed the calculation of EC50
(0.5 nM), compatible with the Kd value for GR binding to
dexamethasone of w5 nM.
Time delay to maximal inhibition
An analysis of the IL-6-luc readout allowed the calculation of
the time to maximal response. The effect of the varying
concentrations of dexamethasone on this time-delay was
determined and was found to be nearly identical irrespective
of whether the concentration of dexamethasone was greater,
or lesser than that of EC50 for response, in all cases being
w200 min (Fig. 3b).
Concentration–overall inhibition response of IL-6 inhibition
In contrast to the lack of effect that different concentrations of
dexamethasone had on time to maximal response, there was a
clear concentration–overall inhibition response relationship as
there was for the concentration–maximal response relationship.
However,theEC50foroverallresponse(10 nM)wasconsistently
higher than that for maximal response (0.5n M ;Fig. 3c).
Figure 1 Summary of data analysis using photomultiplier tubes.
IL-6-luc gene expression is monitored in real time using
photomultiplier tubes. A logarithmic baseline is ﬁtted using relative
light units (RLU) emitted from the IL-6-luc plasmid when not under
the effect of drug treatment. This accounts for luciferase signal
decay. The trend line is then subtracted from the log values of
treatment period to identify drug-induced changes to IL-6-luc
production. This analysis technique allows maximum inhibition,
overall integrated inhibition and the time to maximum inhibition to
be identiﬁed. The treatment was done using 100 nM
dexamethasone.
Figure2 Effect of TNFa and dexamethasone on IL-6-luc expression.
The cells were monitored for basal luciferase expression levels for
48 h, removed from photomultiplier tubes, and treatedwith 5 ng/ml
TNFa and 100 nM dexamethasone, alone and in combination. The
cells were then returned to PMTS and effects of the compounds on
IL-6 promoter activity were monitored for 48 h. The overall
integrated response (area under the ﬁtted trend line) was calculated
for the 48 h time period following treatment. Data from three
independent experiments are presented as meanGS.D.* P!0.05
and **P!0.01 by comparison with vehicle treatment.
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To conﬁrm that the IL-6 response was speciﬁc to those
steroids with proven agonist activity at the glucocorticoid
receptor, a panel of steroids, including glucocorticoid
precursors, was analysed. As expected, the three known
agonists, hydrocortisone, corticosterone and dexamethasone,
were all active in the assay, but hydrocortisone showed a
signiﬁcantly greater overall integrated inhibition than either
dexamethasone or corticosterone (Fig. 4a). In contrast,
21-hydroxyprogesterone had a weak effect that failed to
reach signiﬁcance, and pregnenolone appeared to stimulate
IL-6 promoter activity, as determined by an inverse excursion
of the measurements from the logarithmic trend line (Fig. 4a).
The time delay to maximal inhibition did not differ between
the three agonists (Fig. 4b), but the maximal inhibition seen
with corticosterone was less than that seen with either
hydrocortisone or dexamethasone (Fig. 4c). The maximal
response for the weak ligands (Fig. 4a) did not differ from that
seen with vehicle, and therefore was not plotted (Fig. 4c).
The activity of the steroids was also compared using an
end point assay, with cells harvested at 24 h (Fig. 5). The
maximal inhibition was seen with dexamethasone, therefore
set as 100%. The conventional GR agonists, hydrocortisone
and corticosterone, were both effective, although
corticosterone was markedly less active. Pregnenolone and
17-hydroxy progesterone lacked a signiﬁcant effect, but
21-hydroxyprogesterone signiﬁcantly inhibited the IL-6-luc
expression (Fig. 5).
To determine whether pregnenolone or 17-hydroxypro-
gesterone had the glucocorticoid receptor antagonist activity,
their effects on the hydrocortisone response were measured.
There was no antagonist effect observed (Fig. 6).
Discussion
A major physiological role for glucocorticoids is limiting the
extent of inﬂammatory reaction (McMaster & Ray 2007).
This activity is mediated by the activated glucocorticoid
receptor translocating to the nucleus, and interacting with
other transcription factors and transcriptional modulators
(Chen et al. 2001, Stevens et al. 2003, Garside et al. 2004,
O’Malley 2005, McMaster & Ray 2007). In vivo target cells
are subject to multiple input stimuli, with varying durations of
action. In order to dissect out speciﬁc pathways, a reductionist
approach using cell culture has been successfully employed;
however, the selection of single end points in cross-sectional
analysis may give an incomplete picture of the full, natural
response to stimulation. For this reason, we developed a
genetically engineered IL-6 reporter cell line suitable for a
continuous, non-destructive monitoring of promoter activity.
Previous attempts to generate a cell-based bioassay for
glucocorticoids have relied on transactivation by the GR
(Vermeer et al. 2003), even though this mode of GR action is
Figure 3 (a) Dose–response of IL-6-luc rat-1 stables to
dexamethasone treatment. The cells were monitored for basal
luciferase expression levels for 48 h, removed from photo-
multiplier tubes and treated with various concentrations of
dexamethasone or DMSO control. The cells were then returned
to PMTS and effects of the drug on IL-6 promoter activity were
monitored for 48 h. Maximum inhibition from the data trend
line was used to calculate maximum effect. EC50 was
calculated from the ﬁtted curve. Data from three independent
experiments are presented as meanGS.D. (b) Time to maximum
inhibition. The time from dexamethasone treatment before
maximum inhibition (maximum deviation from trend line) of
IL-6-luc was measured. Data from three independent experi-
ments are presented as meanGS.D. (c) The overall integrated
inhibition of IL-6-luc after dexamethasone treatment. The
overall integrated inhibition was calculated using the area
under the curve approach from the ﬁtted trend line over a
period of 48 h after treatment with various concentrations of
dexamethasone. Data from three independent experiments are
presented as meanGS.D.
A MCMASTER and others . Real-time imaging of Gc action 208
Journal of Endocrinology (2008) 197, 205–211 www.endocrinology-journals.orgnot required for the most important physiological actions of
glucocorticoids (Reichardt et al. 1998).
The reporter cells are robust and capable of survival in
recording media for up to 10 days without detectable effects
on cell viability. Over this period of time, the cells are sealed
and the promoter activity monitored continuously as a result
of exogenous luciferin present in the culture medium. This
further enhances the responsiveness of the system by further
shortening the half-life of the expressed luciferase (Takasuka
et al. 1998). A preliminary analysis of the promoter response
to glucocorticoid suggested a number of robust characteristics
to the curve which could be measured, including the time to
maximal inhibition, maximal inhibition and the overall
integrated inhibition (area under the curve). We set out to
measure these parameters in response to varying glucocorti-
coid concentration and also in response to different steroid
structures.
The maximal inhibition–concentration response was the
most sensitive to glucocorticoid, with the lowest measurable
EC50. In contrast, the time to maximal inhibition showed a
ﬂat concentration–response curve, with no detectable effect
of ligand dose. Interestingly, the EC50 for the overall
inhibition–concentration response, that is the area under
the dose–response curve, was consistently higher than that
seen for maximal effect. An examination of the curves shows
that the time to maximal effect is unaltered by concentration,
but, importantly, the overall duration of response increased
with higher ligand concentration, and hence resulted in an
increased area under the curve.
In vivo glucocorticoids act to oppose the effects of
TNFa, and indeed using the reporter cell system
dexamethasone abolished the TNF response of the IL-6
Figure 5 End point assay of inhibition of IL-6-luc after glucocorti-
coid precursor treatment. The cells were treated with hydrocorti-
sone, corticosterone, dexamethasone, pregnenolone,
21-hydroxyprogesterone or 17-hydroxyprogesterone. A DMSO
control was also included. After 24 h, the cells were harvested and
an end point luciferase assay was performed. Inhibition was plotted
as a percentage of the maximum inhibition induced by dexa-
methasone. Data from three independent experiments are pre-
sented as meanGS.D.* * P!0.01 by comparison with vehicle
treatment.
Figure 4 (a) The overall integrated inhibition of IL-6-luc by steroids.
The cells were monitored for basal luciferase expression levels for
24 h, removed from photomultiplier tubes and treated with
hydrocortisone, corticosterone, dexamethasone, pregnenolone,
progesterone, 21-hydroxyprogesterone or 17-hydroxyprogesterone
(1000 nM). A DMSO control was also included. The cells were then
returned to PMTS and effects of the compounds on IL-6 promoter
activity were monitored for 48 h. The overall integrated inhibition
from ﬁtted baseline was calculated for the 48 h time period
following treatment. Results are displayed as percentage of
maximuminhibition(hydrocortisone). Datafrom threeindependent
experiments are presented as meanGS.D.* P!0.05 and **P!0.01
by comparison with vehicle treatment. (b) The time to maximum
inhibitionofIL-6-lucby steroids.Thetimetomaximuminhibitionof
IL-6-luc after 1000 nM steroid treatment. Data from three
independent experiments are presented as meanGS.D. Hc, hydro-
cortisone; Co, corticosterone; Dex, dexamethasone. (c) The maxi-
mum inhibition of IL-6-luc by glucocorticoid precursors. The level
of maximum inhibition (largest deviation from baseline) was
calculated as a percentage of the maximum inhibition induced by
hydrocortisone. Data from three independent experiments are
presented as meanGS.D. Hc, hydrocortisone; Co, corticosterone;
Dex, dexamethasone. *P!0.05 compared with hydrocortisone.
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using conventional end point, reporter gene assays, and
provides additional reassurance that our real-time reporter
gene approach authentically reports the underlying
biological effect (De Bosscher et al. 2005).
Different molecular structures act on nuclear receptors to
generate clearly distinct conformations of the receptor
(Kauppi et al. 2003, Stevens et al. 2003, Garside et al. 2004).
Therefore, we sought the effects of a panel of closely related
steroid structures, some known to have agonist activity and
others previously ascribed as being inactive. We were able to
show that the three active glucocorticoids indeed had activity
on our reporter cell line, although the characteristics of
response were interesting. As predicted from the earlier
dexamethasone concentration–response study, there was no
effect of steroid structure on the time to maximal response.
However, the overall inhibition was signiﬁcantly greater with
hydrocortisone than with either corticosterone or dexa-
methasone. This was unexpected as dexamethasone is
conventionally viewed as having a greater potency due to
its high binding afﬁnity, and also to showaprolonged duration
of action in vivo due to its greater stability (McCafferty et al.
1981, Rose et al. 1981, Toutain et al. 1984).This second mode
of enhanced activity is unlikely to be relevant in the reporter
cell line, which is not of a steroid metabolising cell type. Cell-
based bioassays of glucocorticoids have also suggested that
dexamethasone is more potent than hydrocortisone (Stevens
et al. 2003, Vermeer et al. 2003). However, most analyses have
focused on a transactivation-based bioassay, and it is now clear
that different target templates show variable, and in many
cases, unpredictable differential responsiveness to different
glucocorticoid ligand structures (Stevens et al. 2003, Wang
et al. 2006). Therefore, the differential potency of hydro-
cortisone may reﬂect a speciﬁc response to the ﬁnal, ligand-
directed structure of the hydrocortisone-bound GR, perhaps
further modiﬁed by its interaction with the DNA-bound
NFkB on the IL-6 promoter (Kauppi et al. 2003, Wang et al.
2006, So et al. 2007). In contrast, hydrocortisone and
dexamethasone showed a similar maximal effect, both greater
than that seen with corticosterone. This reﬂects the different
shape of the response curve seen with the different ligands,
and further emphasises the importance of timing in
determining the measured response. Indeed, there is evidence
from other transcription factors of major short-time frame
variation of transcriptional regulation (Hoffmann et al. 2002).
The only precursor steroid to regulate the expression of the
IL-6 reporter gene was 21-hydroxyprogesterone. This effect
did not reach signiﬁcance in the continuous reporter assay, but
did in the end point assay. The abilityof this steroid to activate
the GR has not been reported before. Out of the
glucocorticoid precursor steroids examined, none showed
antagonist activity in this assay.
Resolving the temporal response of target cells to
glucocorticoid has revealed a number of unexpected ﬁndings.
There is a distinct difference in the EC50 for maximal effect
(amplitude of response), compared with the higher EC50
seen for the overall, integrated response (area under the
curve). There was no concentration effect for the time to
maximal excursion from the trend line. Resolving the steroid
response over time allows a comparison between different
molecular species for these different parameters in a rapid and
robust manner. This approach is expected to be useful for the
correlation against the observed effects in vivo, on different
target tissues and target genes.
In summary, we have developed and validated a new
approach to measure steroid response in vivo. This allows an
accurate, sensitive and robust proﬁling of steroid activity in
real time. This approach has revealed an unexpected
complexity in the relationship between steroid structure and
concentration on the different measurable parameters of
response.
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Figure 6 An investigation of the antagonistic effects of glucocorti-
coid precursors. The cells were treated with hydrocortisone,
pregnenolone, progesterone or 17-hydroxyprogesterone, alone and
in combination. A DMSO control was also included. After 24 h, the
cells were harvested and an end point luciferase assay was
performed. The level of maximum inhibition (largest deviation from
baseline) was calculated as a percentage of the maximum
inhibition. Data from three independent experiments are presented
as meanGS.D.* * P!0.01 by comparison with vehicle treatment.
A MCMASTER and others . Real-time imaging of Gc action 210
Journal of Endocrinology (2008) 197, 205–211 www.endocrinology-journals.orgReferences
De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N,
Hapgood J, Libert C, Staels B, Louw A & Haegeman G 2005 A fully
dissociated compound of plant origin for inﬂammatory gene repression.
PNAS 102 15827–15832.
Brunner M, Ziegler S, Di Stefano AF, Dehghanyar P, Kletter K, Tschurlovits
M, Villa R, Bozzella R, Celasco G, Moro L et al. 2006 Gastrointestinal
transit, release and plasma pharmacokinetics of a new oral budesonide
formulation. British Journal of Clinical Pharmacology 61 31–38.
Chen H, Tini M & Evans RM 2001 HATs on and beyond chromatin. Current
Opinion in Cell Biology 13 218–224.
Garside H, Stevens A, Farrow S, Normand C, Houle B, Berry A, Maschera B
& Ray D 2004 Glucocorticoid ligands specify different interactions with
NF-kB by allosteric effects on the glucocorticoid receptor DNA binding
domain. Journal of Biological Chemistry 279 50050–50059.
Hillier SG 2007 Diamonds are forever: the cortisone legacy. Journal of
Endocrinology 195 1–6.
Hoffmann A, Levchenko A, Scott ML & Baltimore D 2002 The IkB-NF-kB
signaling module: temporal control and selective gene activation. Science
298 1241–1245.
Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, Calles K,
Engstrom O, Harlan J, Muchmore S et al. 2003 The three-dimensional
structures of antagonistic and agonistic forms of the glucocorticoid receptor
ligand-binding domain: RU-486 induces a transconformation that leads to
active antagonism. Journal of Biological Chemistry 278 22748–22754.
McCaffertyJ, BrophyTR, Yelland JD, Cham BE, Bochner F &Eadie MJ 1981
Intraoperative pharmacokinetics of dexamethasone. British Journal of Clinical
Pharmacology 12 434–436.
McMaster A & Ray DW 2007 Modelling the glucocorticoid receptor and
producing therapeutic agents with anti-inﬂammatory effects but reduced
side-effects. Experimental Physiology 92 299–309.
O’Malley BW 2005 A life-long search for the molecular pathways of steroid
hormone action. Molecular Endocrinology 19 1402–1411.
Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R,
Gass P, Schmid W, Herrlich P, Angel P et al. 1998 DNA binding of the
glucocorticoid receptor is not essential for survival. Cell 93 531–541.
Rose JQ, Yurchak AM, Meikle AW & Jusko WJ 1981 Effect of smoking on
prednisone, prednisolone, and dexamethasone pharmacokinetics. Journal of
Pharmacokinetics and Biopharmaceutics 9 1–14.
Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D & Pauwels R
1982 Pharmacokinetics and metabolism of budesonide, a selective
glucocorticoid. European Journal of Respiratory Diseases 122 86–95.
Samtani MN & Jusko WJ 2005 Comparison of dexamethasone pharmaco-
kinetics in female rats after intravenous and intramuscular administration.
Biopharmaceutics and Drug Disposition 26 85–91.
Samtani MN & Jusko WJ 2007 Quantiﬁcation of dexamethasone and
corticosterone in rat bioﬂuids and fetal tissue using highly sensitive
analytical methods: assay validation and application to a pharmacokinetic
study. Biomedical Chromatography 21 585–597.
Singh D, Tutuncu A, Lohr I, Carlholm M & Polanowski T 2007 Budesonide
administered using chloroﬂuorocarbon and hydroﬂuoroalkane pressurized
metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical
equivalence. International Journal of Clinical Pharmacology and Therapeutics
45 485–495.
So AY, Chaivorapol C, Bolton EC, Li H & Yamamoto KR 2007
Determinants of cell- and gene-speciﬁc transcriptional regulation by the
glucocorticoid receptor. PLoS Genetics 3 e94.
Stevens A, Garside H, Berry A, Waters C, White A & Ray D 2003
Dissociation of steroid receptor coactivator 1 and nuclear receptor
corepressor recruitment to the human glucocorticoid receptor by
modiﬁcation of the ligand-receptor interface: the role of tyrosine 735.
Molecular Endocrinology 17 845–859.
Takasuka N, White MR, Wood CD, Robertson WR & Davis JR 1998
Dynamic changes in prolactin promoter activation in individual living
lactotrophic cells. Endocrinology 139 1361–1368.
Toutain PL, Brandon RA, de Pomyers H, Alvinerie M & Baggot JD 1984
Dexamethasone and prednisolone in the horse: pharmacokinetics and action
on the adrenal gland. American Journal of Veterinary Research 45 1750–1756.
Vermeer H, Hendriks-Stegeman BI, van den Brink CE, van der Saag PT,
van der BB, Buul-Offers SC & Jansen M 2003 A novel speciﬁc bioassay for
the determination of glucocorticoid bioavailability in human serum.
Clinical Endocrinology 59 49–55.
Wang JC, Shah N, Pantoja C, Meijsing SH, Ho JD, Scanlan TS & Yamamoto
KR 2006 Novel arylpyrazole compounds selectively modulate glucocor-
ticoid receptor regulatory activity. Genes and Development 20 689–699.
Yoo SH, Yamazaki S, Lowrey PL, Shimomura K, Ko CH, Buhr ED, Siepka
SM, Hong HK, Oh WJ, Yoo OJ et al. 2004 PERIOD2::LUCIFERASE
real-time reporting of circadian dynamics reveals persistent circadian
oscillations in mouse peripheral tissues. PNAS 101 5339–5346.
Received in ﬁnal form 12 February 2008
Accepted 27 February 2008
Made available online as an Accepted Preprint
27 February 2008
Real-time imaging of Gc action . A MCMASTER and others 211
www.endocrinology-journals.org Journal of Endocrinology (2008) 197, 205–211